GnRH Agonists and Antagonists

[1]  J. Bogstad,et al.  Cumulative live birth rates after one ART cycle including all subsequent frozen–thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols , 2017, Human reproduction.

[2]  B. Fauser,et al.  Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. , 2017, Fertility and sterility.

[3]  R. Boostanfar,et al.  Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis. , 2016, Reproductive biomedicine online.

[4]  J. Bogstad,et al.  Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. , 2016, Human reproduction.

[5]  B. Tarlatzis,et al.  Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol , 2016, PloS one.

[6]  Ying-pu Sun,et al.  Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization/ intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: a systematic review and meta-analysis , 2014, Reproductive Biology and Endocrinology.

[7]  F. Broekmans,et al.  Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulation , 2013, Reproductive Biology and Endocrinology.

[8]  B. Tarlatzis,et al.  Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH. , 2012, Reproductive biomedicine online.

[9]  K. Diedrich,et al.  Gonadotropin-Releasing Hormone Antagonists for Assisted Reproductive Techniques , 2012, Drugs.

[10]  E. Kolibianakis,et al.  No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH. , 2011, Reproductive biomedicine online.

[11]  Jiayin Liu,et al.  Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF. , 2011, Human reproduction.

[12]  F. Broekmans,et al.  Gonadotrophin-Releasing Hormone Antagonists for Assisted Reproductive Technology , 2011, The Cochrane database of systematic reviews.

[13]  M. Depenbusch,et al.  Cumulative live birth rates after GnRH-agonist triggering of final oocyte maturation in patients at risk of OHSS: a prospective, clinical cohort study. , 2010, European journal of obstetrics, gynecology, and reproductive biology.

[14]  P. Devroey,et al.  Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. , 2009, Human reproduction update.

[15]  E. Kolibianakis,et al.  Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. , 2007, Human reproduction update.

[16]  K. Diedrich,et al.  Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. , 2007, Human reproduction.

[17]  E. Kolibianakis,et al.  Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. , 2006, Human reproduction update.

[18]  D. Finas,et al.  Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol. , 2006, Fertility and sterility.

[19]  E. Kolibianakis,et al.  GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. , 2006, Human reproduction update.

[20]  E. Kolibianakis,et al.  GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. , 2006, Reproductive biomedicine online.

[21]  G. Serour,et al.  Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol. , 2005, Reproductive biomedicine online.

[22]  D. Finas,et al.  Short Communication: FSH Time-Concentration Profiles Before and After Administration of 0.25 mg Cetrorelix in the GnRH-Antagonist Multiple-Dose Protocol for Ovarian Hyperstimulation , 2004, Journal of Assisted Reproduction and Genetics.

[23]  M. Aboulghar,et al.  GnRH antagonist in assisted reproduction: a Cochrane review. , 2002, Human reproduction.

[24]  A. Schueler,et al.  Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women. , 2001, Fertility and sterility.

[25]  H. Derendorf,et al.  Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH‐RH antagonist, after subcutaneous administration in healthy premenopausal women , 2000, Clinical pharmacology and therapeutics.

[26]  F. Bissonnette,et al.  Effects of functional ovarian cysts detected on the 7th day of gonadotropin-releasing hormone analog administration on the outcome of IVF treatment. , 2000, Fertility and sterility.

[27]  J. Oberyé,et al.  Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. , 1999, Fertility and sterility.

[28]  J. Oberyé,et al.  Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. , 1999, Fertility and sterility.

[29]  R. Hermann,et al.  Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. , 1998, Human reproduction.

[30]  A. Schally,et al.  Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. , 1995, Human reproduction.

[31]  D. Klingmüller,et al.  Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling women. , 1994, European journal of endocrinology.

[32]  J. Collins,et al.  The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. , 1992, Fertility and sterility.

[33]  G. Goldman,et al.  Ovarian cyst formation: a complication of gonadotropin-releasing hormone agonist therapy. , 1989, Fertility and sterility.

[34]  J. Yovich,et al.  Reduced in‐vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase , 1985, British journal of obstetrics and gynaecology.

[35]  E. Knobil,et al.  The neuroendocrine control of the menstrual cycle. , 1980, Recent progress in hormone research.

[36]  E. Knobil.  On the control of gonadotropin secretion in the rhesus monkey. , 1974, Recent progress in hormone research.

[37]  A. Schally,et al.  Isolation of the luteinizing hormone and follicle-stimulating hormone-releasing hormone from porcine hypothalami. , 1971, The Journal of biological chemistry.